Research of the Top 20 Companies Investing in R&D Shows Revenue Derived
from New Products Accounted for Just 16% of Total Revenue in 2006
PHILADELPHIA and LONDON, Sept. 24 /PRNewswire/ -- The Centre for Medicines Research International Ltd. (CMR), a Thomson business, today announced it has published the CMR 2007 International Pharmaceutical R&D Factbook, an indispensable reference and business planning tool for decision makers in pharmaceutical R&D, corporate finance, business strategy, marketing planning and corporate communications. The Factbook offers a comprehensive and up-to-date overview of emerging trends in worldwide pharmaceutical R&D, enabling users to include data in presentations and reports.
CMR's research of the top 20 companies investing in R&D shows that revenue derived from new products (those launched within the last five years) accounted for just 16% of total revenue in 2006, continuing the industry's potential exposure to patent expiry. And although the cost of R&D continues to rise, there's no sign of a sustained upturn in the number of new products reaching the market. Also noteworthy this year is the continuing expansion of clinical development in traditionally non-core countries (that is, countries other than the eight core countries: Canada, France, Germany, Italy, Japan, Spain, UK and US). In 2005, nearly 50% of patients recruited to clinical trials came from these non-core regions.
"The CMR Factbook provides valuable insight into R&D activity within the pharmaceutical industry," says Peter Joshua, vice president and general manager, CMR International. "Our research can help users make informed decisions that can reduce development times, improve efficiency, implement more accurate performance target-setting and predictive modeling, and gauge internal performance against competitors."
Underlying data found in the Factbook are exclusively from primary
sources and include all major pharmaceutical companies
|SOURCE Thomson Scientific|
Copyright©2007 PR Newswire.
All rights reserved